Chembio Diagnostic Systems, Inc. (OTC BB:CEMI)

Chembio Diagnostic Systems, Inc develops, manufactures and markets rapid tests for the detection of HIV and certain other infectious diseases. The company's current products are based upon single path lateral flow, rapid test technology platforms using proprietary and/or in-licensed technology. Chembio's patented Dual Path Platform (DPP™) is now being employed to develop several new high performance rapid test products in collaboration with others.

Chembio's HIV assays have been incorporated into the World Health Organization (WHO) Bulk Procurement Scheme and the USAID blanket Waiver List which allows them to be procured with U.S. government funds. Two of the company's assays have been approved by the U.S. FDA for sale in the United States. This enables the company to participate in the growing U.S. market which is estimated to be a $50 million market.

Chembio Diagnostic Systems, Inc. operates a cGMP/QS (Good Manufacturing Facility/Quality Systems) manufacturing facility that is registered with the US FDA (Food and Drug Administration). The facility includes dedicated cGMP process manufacturing, Quality Control and R&D laboratories. The company manufactures class II and class III in vitro diagnostic devices.